Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AnHeart Raises $20 Million for ROS1/NTRK Inhibitor to Treat NSCLC

publication date: Aug 14, 2020

AnHeart Therapeutics of Hangzhou raised over $20 million in an over-subscribed Series A+ financing round. The company will use the proceeds to support global Phase II trials of taletrectinib, a selective next-gen ROS1/NTRK inhibitor, along with advancing its other oncology assets. Because taletrectinib is capable of crossing the blood-brain barrier, it is expected to be effective against brain metastases in NSCLC. AnHeart will test the candidate in patients who have NSCLC with ROS1 mutations or advanced/metastatic solid tumors with NTRK mutations. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here